# Molina Healthcare, Inc. (MOH)

> Source: Nexqual · https://nexqual.com/MOH · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Molina Healthcare, Inc. (MOH), nexqual.com/MOH" · informational, not investment advice.

**Price:** USD 216.64 (+0.81% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 214.9 · day 206.7–225.88 · 52w 121.06–244.89 · market cap $11.3B · NYQ

## Key facts
- Last four reported quarters (through Sep 30, 2026): revenue $44.1B, net income -$48.0M (-0.1% margin), free cash flow $238M (SEC filings).
- 3 of 80 tracked superinvestors hold MOH (13F, Q2 2026 (1 investor on Q3 2025, filed early)): 1 new, 0 added, 1 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $3.4M; 2 not under a Rule 10b5-1 plan ($3.4M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.95 on a 1–5 scale) (19 analysts), mean target USD 214.94 (range 147–266).
- Total return with dividends: 1Y +34.6% vs S&P 500 +14.9%; 5Y -27.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-21, EPS estimate USD 0.51, revenue estimate $11.7B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $27.8B | $32.0B | $34.1B | $40.6B | $45.4B | $44.1B |
| Gross profit | $4.07B | $4.80B | $5.40B | $6.22B | $5.94B | — |
| Operating income | $1.02B | $1.17B | $1.57B | $1.71B | $781M | $172M |
| Net income | $659M | $792M | $1.09B | $1.18B | $472M | -$48.0M |
| EPS (diluted) | $11.25 | $13.55 | $18.77 | $20.42 | $8.92 | — |
| Free cash flow | $2.04B | $682M | $1.58B | $544M | -$636M | $238M |
| Gross margin | 14.6% | 15.0% | 15.9% | 15.3% | 13.1% | — |
| Operating margin | 3.7% | 3.7% | 4.6% | 4.2% | 1.7% | 0.4% |
| Net margin | 2.4% | 2.5% | 3.2% | 2.9% | 1.0% | -0.1% |
| Revenue growth | +43.0% | +15.1% | +6.6% | +19.3% | +11.7% | — |
| Cash + short-term investments | $7.64B | $7.50B | $9.11B | $8.99B | $8.26B | — |
| Total debt | $2.17B | $2.18B | $2.18B | $2.92B | $3.77B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)
P/S 0.3x · EV/EBITDA 19.5x · EV/Sales 0.1x · P/FCF 47.5x · P/B 2.7x · FCF yield 2.10% · Earnings yield -0.42% · Buyback yield (TTM) 0.00% · Net cash $4.81B · EV $6.50B
P/E at fiscal year-ends: Dec 2025 19.4x, Dec 2024 14.2x, Dec 2023 19.2x.

## Superinvestors (SEC 13F-HR, Q2 2026)
3 of 80 tracked investors hold MOH (1 investor on Q3 2025, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Michael Burry | Scion Asset Management | 35.11% | $23.9M | New position | Q3 2025 |
| Seth Klarman | Baupost Group | 2.68% | $145M | Unchanged | Q2 2026 |
| Bill Nygren | Oakmark Funds | 0.29% | $219M | Reduced -2.1% | Q2 2026 |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | Hebert Maurice | Chief Accounting Officer | 600 | $115K | 4.5% | No | Too little history (no open-market trades in 2025) |
| 2026-05-11 | Barlow Jeff D. | Chief Legal Officer | 17,811 | $3.3M | 21% | No | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.95 on a 1–5 scale), 19 analysts; mean target USD 214.94 (low 147, high 266).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | Wells Fargo | Target lowered | Equal-Weight | $235 → $220 |
| 2026-07-24 | Truist Securities | Target lowered | Hold | $250 → $225 |
| 2026-07-24 | RBC Capital | Target lowered | Sector Perform | $248 → $218 |
| 2026-07-24 | Barclays | Target lowered | Underweight | $184 → $180 |
| 2026-07-14 | TD Cowen | Target raised | Hold | $163 → $230 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $205 → $250 |
| 2026-07-13 | Wells Fargo | Target raised | Equal-Weight | $159 → $235 |
| 2026-07-09 | RBC Capital | Target raised | Sector Perform | $216 → $248 |
| 2026-07-09 | Barclays | Target lowered | Underweight | $199 → $184 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +34.6% | -27.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +34.7% | -6.2% |
| Volatility (annualized) | 52.4% | 39.5% |
| Max drawdown | -39.3% (Jan 2026→Feb 2026) | -68.2% (Mar 2024→Feb 2026) |

## Peers (Healthcare Plans)
OSCR (Oscar Health, Inc.) USD 33.32 -0.39% · CNC (Centene Corporation) USD 71.24 +1.42% · HUM (Humana Inc.) USD 420.97 -1.05% · CLOV (Clover Health Investments, Corp) USD 4.73 -1.05% · PGNY (Progyny, Inc.) USD 29.12 +2.39% · ALHC (Alignment Healthcare, Inc.) USD 8.43 -0.12%

## More
Full page: https://nexqual.com/MOH · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name MOH in their own reports (relationship from MOH's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | Evolent Health, Inc. (EVH) | 10-K 2026-02-25 | "Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $0.51 | $0.54 | -5.9% | $11.70B | 7 |
| Next quarter (ends 2027-03-31) | $3.06 | $3.05 | +0.3% | $11.71B | 13 |
| Current fiscal year (ends 2026-12-31) | $5.25 | $5.22 | +0.7% | $44.54B | 19 |
| Next fiscal year (ends 2027-12-31) | $9.58 | $8.55 | +12.0% | $47.40B | 5 |